126 related articles for article (PubMed ID: 12808880)
1. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes.
Wiedeman PE; Trevillyan JM
Curr Opin Investig Drugs; 2003 Apr; 4(4):412-20. PubMed ID: 12808880
[TBL] [Abstract][Full Text] [Related]
2. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
Pei Z
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
[TBL] [Abstract][Full Text] [Related]
3. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
Nagakura T; Yasuda N; Yamazaki K; Ikuta H; Tanaka I
Metabolism; 2003 Jan; 52(1):81-6. PubMed ID: 12524666
[TBL] [Abstract][Full Text] [Related]
4. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
5. Incretins and other peptides in the treatment of diabetes.
Todd JF; Bloom SR
Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
[TBL] [Abstract][Full Text] [Related]
6. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
Diamant M; Bunck MC; Heine RJ
Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
[TBL] [Abstract][Full Text] [Related]
7. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
Triplitt C; Wright A; Chiquette E
Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716
[TBL] [Abstract][Full Text] [Related]
8. Incretin-based therapies: mimetics versus protease inhibitors.
Brubaker PL
Trends Endocrinol Metab; 2007 Aug; 18(6):240-5. PubMed ID: 17629492
[TBL] [Abstract][Full Text] [Related]
9. Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats.
Yasuda N; Inoue T; Nagakura T; Yamazaki K; Kira K; Saeki T; Tanaka I
J Pharmacol Exp Ther; 2004 Aug; 310(2):614-9. PubMed ID: 15039452
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?
McIntosh CH; Demuth HU; Pospisilik JA; Pederson R
Regul Pept; 2005 Jun; 128(2):159-65. PubMed ID: 15780435
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.
Deacon CF; Holst JJ
Int J Biochem Cell Biol; 2006; 38(5-6):831-44. PubMed ID: 16242377
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Langley AK; Suffoletta TJ; Jennings HR
Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
[TBL] [Abstract][Full Text] [Related]
13. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
Kirby M; Yu DM; O'Connor S; Gorrell MD
Clin Sci (Lond); 2009 Sep; 118(1):31-41. PubMed ID: 19780719
[TBL] [Abstract][Full Text] [Related]
14. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus.
McIntosh CH; Demuth HU; Kim SJ; Pospisilik JA; Pederson RA
Int J Biochem Cell Biol; 2006; 38(5-6):860-72. PubMed ID: 16442340
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.
Idris I; Donnelly R
Diabetes Obes Metab; 2007 Mar; 9(2):153-65. PubMed ID: 17300591
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 derivatives and dipeptidyl peptidase-IV inhibitors. New hope for the treatment of type-2 diabetes.
Al-Omar MA; Al-Arifi MN
Saudi Med J; 2005 Oct; 26(10):1511-5. PubMed ID: 16228047
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement.
Mest HJ
Curr Opin Investig Drugs; 2006 Apr; 7(4):338-43. PubMed ID: 16625820
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
19. The role of vildagliptin in the management of type 2 diabetes mellitus.
Kleppinger EL; Helms K
Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
[TBL] [Abstract][Full Text] [Related]
20. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes.
Nielsen LL
Drug Discov Today; 2005 May; 10(10):703-10. PubMed ID: 15896683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
